NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Shakti Singh · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · 2024 · $134,800 — PROJECT SUMMARY: Candidate’s Career Development: Dr. Shakti Singh, an accomplished immunologist, presently holds the positions of Investigator and Assistant Professor at The Lundquist Institute (TLI) and the University of California, Los Angeles (UCLA), respectively. Over the past seven years at TLI…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Hao Yu · E&E BIOCLUB LLC · 2024 · $300,518 — PROJECT SUMMARY The success of mRNA-based vaccines and their modular technology have propelled RNA- based medicines from a relatively niche technology into the mainstream. As RNA-based medicines research intensifies, the manufacturing capacity of RNA is strained. This issue is exacerbated by the unp…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Michael R. Farzan · BOSTON CHILDREN'S HOSPITAL · 2024 · $891,681 — PROJECT SUMMARY What is the shortest path from the human antibody repertoire to sera that protects from an HIV-1 challenge? We propose here that this pathway starts from B-cell receptors (BCRs) with long, tyrosine-sulfated heavy- chain CDR3s (HCDR3s) encoded by D3-family of diversity (D) chain segme…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
STEPHEN J MCSORLEY · UNIVERSITY OF CALIFORNIA AT DAVIS · 2024 · $225,839 — PROJECT SUMMARY A successful vaccine for systemic Salmonella infections will need to induce Th1 memory cells, but the tissue location and required functionality of these cells is poorly understood. Our preliminary data show that liver Tissue Resident Memory (TRM) CD4 T cells express higher levels of…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
James L. Gulley · DIVISION OF BASIC SCIENCES - NCI · 2024 · $270,790 — Four CCR projects are currently supported by this Cancer Moonshot Bench to Beside and Back award: 1) TME informed NK cell therapy for pediatric sarcomas, led by Rosandra Kaplan (CCR) and Timothy Cripe (Nationwide Children's Hospital). The overall goal of this project is to develop natural killer (NK…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $162,032 — ABSTRACT ADMINISTRATION CORE The Administrative Core will support the scientific and programmatic activities of our IPCAVD Program and provide the necessary infrastructure for the Program to achieve its overall research objectives and milestones in the most efficient and effective manner. This Core …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
ELLIS L REINHERZ · DANA-FARBER CANCER INST · 2024 · $102,537 — SUMMARY – CORE A The Administrative Core A is requested to facilitate internal interactions among PIs of Projects 1-2, leaders of the four technology components, Core B (Antibody Neutralization), and the IAVI Biobank at both on- and off- campus sites as well as with the NIAID. Core A is responsible …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Steven James Madore · UNIVERSITY OF FLORIDA · 2024 · $43,615 — SHARED RESOURCE MANAGEMENT: ABSTRACT The University of Florida Health Cancer Center (UFHCC) members benefit from access to the UFHCC-managed Biostatistics and Quantitative Sciences Shared Resource (BQS-SR) and the institutionally-managed Flow Cytometry and Confocal Microscopy Shared Resource (CYT-SR…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Florian Krammer · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $191,272 — Summary SARS-CoV-2 vaccines have been developed in record time and are now widely used in many different countries around the globe. Project 1 will focus on characterizing immune signatures associated with SARS-CoV-2 immunization using different vaccine types. In Aim 1 we will leverage existing bios…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Joseph Paul Zackular · UNIVERSITY OF PENNSYLVANIA · 2024 · $380,746 — SUMMARY - PROJECT 2 (ANTIGEN DISCOVERY) Clostridium difficile is a spore-forming pathogen that causes a wide range of gastrointestinal (GI) disorders varying in severity from mild diarrhea to fulminant colitis and death. Difficulties in treating infections with conventional antibiotics and increasin…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
E. John Wherry · MASSACHUSETTS GENERAL HOSPITAL · 2024 · $356,453 — Project Abstract Human immunology has changed radically in the past decade, accelerated, in part, by the COVID-19 pandemic. Despite this progress, we still lack knowledge of how to specifically induce optimal vaccine-induced T and B cell responses. One major gap in human immunology is the inability …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $435,818 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2024 · $430,315 — Project Summary An estimated 350,000 people in the United States become infected with Coccidioides annually. There is an unmet need to develop better chemotherapies and a vaccine for active immunization and/or immunotherapy against coccidioidomycosis (CM). We have previously created a recombinant ch…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Pamela J Bjorkman · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2024 · $1,724,205 — PROJECT SUMMARY SHIV-infected rhesus macaques (RMs) develop HIV-1 broadly neutralizing antibodies (bNAbs) via Env-antibody (Ab) co-evolutionary pathways that recapitulate events in HIV-1 infected humans. This includes the frequency of bNAb induction, the viral epitopes targeted, and the immunogeneti…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Boris Dominik Juelg · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $715,267 — Project 2: Summary While traditionally regarded as a generalized tolerogenic state, emerging data suggest that pregnancy is far from a simple anti-inflammatory shift but is characterized by dramatic shifts from inflammation to tolerance over the course of pregnancy, to accommodate changes in the …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $800,602 — ABSTRACT PROJECT ONE We have reported on the design of a germline-targeting recombinant (rec) HIV-1 Env-derived immunogen, 426c.Mod.Core-C4b, that activates naïve B cells that express germline VRC01-class BCRs and on “booster” rec protein immunogen, HxB2.WT.Core-C4b, that improves the maturation of …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Sean PJ Whelan · WASHINGTON UNIVERSITY · 2024 · $6,793,772 — SUMMARY. The long term goals of Project 3 of the Respiro, Rubula, Peribunya, Phenui (R2P2) ReVAMPP are to use a prototype pathogen approach to identify and validate generalizable vaccine strategies against peribunyaviruses, and advance therapeutically useful monoclonal antibodies (mAb). To achieve t…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2024 · $1,343,022 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
MARK LEWIS · BIOQUAL, INC. · 2024 · $849,354 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
KATERINA ANDRIANOVA · FLAG BIO, INC. · 2024 · $594,566 — The contractor will develop mRNAFlag as a vaccine adjuvant. mRNAFlag is an mRNA transcript that encodes for the deimmunized TLR5 agonist GP532. mRNAFlag would be developed within the context of an influenza mRNA vaccine, using an A/California/07/2009(H1N1) hemagglutinin in an LNP formulation used …